<DOC>
	<DOCNO>NCT00134641</DOCNO>
	<brief_summary>The purpose study determine combination gemcitabine vinorelbine effective treating patient advance soft tissue sarcoma .</brief_summary>
	<brief_title>Study Gemcitabine Vinorelbine Soft Tissue Sarcomas</brief_title>
	<detailed_description>Patients receive gemcitabine vinorelbine week two week one week chemotherapy ( 1 cycle equal 21 day ) . Gemcitabine vinorelbine administer day 1 day 8 cycle . Blood test perform day chemotherapy administer . A CT scan do every 2 cycle ( approximately every 6 week ) determine effect chemotherapy sarcoma . A physical exam perform start chemotherapy least every three week thereafter . Patients remain study long disease progress unacceptable side effect .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Histologic diagnosis unresectable metastatic soft tissue sarcoma Measurable disease outside prior irradiated area ECOG performance status 0,1 , 2 . 0 1 prior regimen advance disease . Adequate end organ function , define bilirubin &lt; 1.8 ; SGOT/SGPT &lt; 2.5 x upper limit normal ( ULN ) ; creatinine &lt; 1.5 x ULN . Negative pregnancy test Life expectancy great 3 month Patient receive investigational agent within 28 day first day study drug dose Two prior regimen advance disease Prior gemcitabine vinorelbine Another primary malignancy Grade III/IV cardia dysfunction Female patient pregnant breastfeed Severe and/or lifethreatening medical disease Known diagnosis HIV infection Prior chemotherapy within 4 week prior study entry Major surgery within 2 week prior study entry Known hypersensitivity either gemcitabine vinorelbine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>soft tissue sarcoma</keyword>
	<keyword>metastatic soft tissue sarcoma</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>vinorelbine</keyword>
</DOC>